Business Context and Reporting Period
This Form 8-K is a current report filed by Zentalis Pharmaceuticals, Inc. on June 21, 2022. The filing addresses a corporate governance event regarding the departure of a senior officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The material change reported is the resignation of Alexis M. Pinto as Chief Legal Officer and Secretary of the Company. The resignation was notified on June 21, 2022, and is effective as of July 5, 2022.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on business strategy, or discussion of risks and contingencies beyond the specific event of the officer's departure.
Investor Verification Checklist
- Confirm the effective date of Alexis M. Pinto's resignation (July 5, 2022).
- Verify if a successor has been appointed for the roles of Chief Legal Officer and Secretary.
- Review subsequent filings for any impact on the company's legal operations or compliance status.